List of a few commercially available skin substitutes and their properties
Sl no. | Skin substitute | Source | Characteristics | Advantages | Limitations | Ref. |
---|---|---|---|---|---|---|
1 | Alloderm SelectTM RTM | Human tissue matrix | Acellular dermal and basement membrane substitute | Intact basement membrane with appropriate dermal porosity | Not guaranteed to be free of all pathogens, high cost, long-term evaluation of carcinogenic or mutagenic potential is pending | [15–17] |
2 | Dermagraft® | Cryopreserved human fibroblasts seeded on bioabsorbable mesh | Dermal substitute used for the treatment of diabetic wounds | Treat full-thickness diabetic foot ulcers in patients who have an adequate blood supply | Absence of immune, vascular cells. Not useful for infected wounds | [15] |
3 | Glyaderm® | NaOH treated & glycerol preserved human cadaver skin | Acellular dermis is used to reconstruct full-thickness wounds arising from burns and injuries | Cost-effective, eliminate dermal antigenic structures | It is a two-step procedure, where Glyaderm application is followed by split-thickness autograft procedure | [18, 19] |
4 | IntegraTM | Dermal substitute consisting of bovine tendon collagen with chondroitin 6 sulfate with silicone surface layer | Acute deep partial-thickness, full-thickness burns, burn reconstruction applications | Availability and shelf storage, promote vascularization in poor recipient sites | Collection of hematomas and seromas is difficult. Lack of intrinsic antibacterial property | [15, 20–25] |
5 | MatriDerm® | Bovine source. Collagen-elastin hydrolysate, gamma-treated | Soft tissue defects, full thickness or deep dermal burns, and chronic wounds | Better cosmetic appearance, superior resilience, standardized option | Lack of more scientific evidence | [23, 26] |
6 | ApligrafTM | Bi-layered, prepared from neonatal foreskin-derived keratinocytes and fibroblasts with bovine type I collagen | Full-thickness diabetic wounds | Viable method of burn wound treatments, better cosmetic results, shelf-life of 5 days at room temperature | Expensive, short shelf life, instability at the wound bed | [27, 28] |
7 | Biobrane® | Inner layer of nylon mesh and an outer layer of silastic | Burn wounds (partial-thickness burns in children) | Experience less pain and requirements of pain medications, reduces time required for wound healing | Permanent scarring in partial-thickness scald wounds | [28] |
8 | Hyalomatrix® | Bilayer hyaluronan base scaffold with autologous fibroblast, and outer silicone layer present | Burn wounds and chronic wounds | Delivers hyaluronan to the wound bed | Less rigidity than some collagen-based products, risks separation with tissues under tension | [28, 29] |
9 | Transcyte® (or Dermagraft-TC) | Human fibroblast-derived, polymer membrane and newborn human fibroblast cells cultured on a porcine collagen coated nylon mesh | Licensed by the FDA for use in burns | Spontaneous separation occurs which indicates wound bed healing. Biocompatible, protects the burn wound surface from environmental insults | High cost, multiple applications required | [30–32] |
10 | Dermagraft® | Similar to Transcyte® but it lacks the silicone layer. Contains viable fibroblasts | Used in diabetic foot ulcers | Stimulate wound healing in chronic wounds | Should be used along with standard wound care regimens, useful in patients who have adequate blood supply to the involved foot | [33, 34] |
ASD: Writing—original draft, Writing—review & editing. NM and RM: Conceptualization, Writing—review & editing. All authors read and approved the submitted version
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
ASD acknowledges Kerala State Council for Science, Technology and Environment (KSCSTE), Thiruvananthapuram, Kerala, India, for providing financial support through the fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.